Publication: Thrombozytenaggregationshemmer: Was sind die Risiken?
Thrombozytenaggregationshemmer: Was sind die Risiken?
Date
Date
Date
Citations
Curkovic, I., Egbring, M., & Kullak-Ublick, G. A. (2013). Thrombozytenaggregationshemmer: Was sind die Risiken? Praxis, 102, 1243–1250. https://doi.org/10.1024/1661-8157/a001431
Abstract
Abstract
Abstract
The most common risks related to platelet inhibitor therapy are bleeding, drug-drug interactions and therapeutic failure. The new substances prasugrel and ticagrelor are more potent platelet inhibitiors than clopidogrel. This reduces the incidence of ischemic events, but also potentially increases the bleeding risk. Clopidogrel therapy has up to 20% non-response rates, which can partially be explained by genetic polymorphisms and drug-drug interactions. Currently no evidence exists that ticagrelor or prasugrel efficacy is affected by
Metrics
Views
Additional indexing
Other titles
Other titles
Other titles
Creators (Authors)
- Curkovic, Ivanka
- Egbring, Marco
- Kullak-Ublick, Gerd A
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
Publisher
Publisher
Publisher
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Views
Citations
Curkovic, I., Egbring, M., & Kullak-Ublick, G. A. (2013). Thrombozytenaggregationshemmer: Was sind die Risiken? Praxis, 102, 1243–1250. https://doi.org/10.1024/1661-8157/a001431
